Abstract
Osteosarcoma (OS) is a high-grade intraosseous malignancy. Twenty to thirty percent of OS patients react poorly to standard therapy with a combination of surgical resection and chemotherapy. It is necessary to find molecules that play an important role in this. This study explored the role of TRIM4 in OS chemotherapy sensitivity and malignant progression. The expression of TRIM4 in OS tissues and cells was examined by RT-qPCR, immunohistochemical staining, and western blot. Specific siRNA was transfected into U2-OS and SAOS2 cells to target TRIM4. Cell biological behavior was examined by CCK-8, Transwell, and flow cytometry experiments. Cisplatin-resistant SAOS2 (SAOS2-Cis-R) cells were established, and the effect of TRIM4 expression on the cisplatin response of SAOS2 cells was tested. Knockdown of TRIM4 significantly inhibited the proliferation, migration, and invasion of U2-OS and SAOS2 cells and induced apoptosis. TRIM4 expression was significantly higher in chemotherapy-resistant OS tissues compared to chemotherapy-sensitive OS tissues. Furthermore, the expression of TRIM4 in SAOS2-Cis-R cells was significantly increased compared to parental SAOS2 cells. Moreover, overexpression of TRIM4 enhanced cisplatin resistance in parental SAOS2 cells, while the downregulation of TRIM4 expression enhanced cisplatin sensitivity of SAOS2-Cis-R cells. High TRIM4 expression might be associated with malignant progression and poor response to chemotherapy response of OS. Targeting TRIM4 may be beneficial for OS treatment or combination therapy.
Similar content being viewed by others
Data Availability
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
References
Gardner, H. L., Sivaprakasam, K., Briones, N., Zismann, V., Perdigones, N., Drenner, K., et al. (2019). Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. Communications Biology, 2, 266. https://doi.org/10.1038/s42003-019-0487-2
Savage, S. A., & Mirabello, L. (2011). Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma, 2011, 548151. https://doi.org/10.1155/2011/548151
Rickel, K., Fang, F., & Tao, J. (2017). Molecular genetics of osteosarcoma. Bone, 102, 69–79. https://doi.org/10.1016/j.bone.2016.10.017
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015). Osteosarcoma: Current treatment and a collaborative pathway to success. Journal of Clinical Oncology, 33(27), 3029–3035. https://doi.org/10.1200/JCO.2014.59.4895
Canet, L. M., Sanchez-Maldonado, J. M., Caliz, R., Rodriguez-Ramos, A., Lupianez, C. B., Canhao, H., et al. (2019). Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. The Pharmacogenomics Journal, 19(1), 83–96. https://doi.org/10.1038/s41397-018-0057-x
Tomar, D., Prajapati, P., Lavie, J., Singh, K., Lakshmi, S., Bhatelia, K., et al. (2015). TRIM4; a novel mitochondrial interacting RING E3 ligase, sensitizes the cells to hydrogen peroxide (H2O2) induced cell death. Free Radical Biology and Medicine, 89, 1036–1048. https://doi.org/10.1016/j.freeradbiomed.2015.10.425
Li, C., & He, L. (2023). The relationship between preeclampsia and arsenic concentration in the peripheral blood shows association rather than causation. Biological Trace Element Research, 201(1), 2–3. https://doi.org/10.1007/s12011-022-03157-y
Sun, X., Xian, H., Tian, S., Sun, T., Qin, Y., Zhang, S., et al. (2016). A hierarchical mechanism of RIG-I ubiquitination provides sensitivity, robustness and synergy in antiviral immune responses. Scientific Reports, 6, 29263. https://doi.org/10.1038/srep29263
Tian, Y., Arai, E., Makiuchi, S., Tsuda, N., Kuramoto, J., Ohara, K., et al. (2020). Aberrant DNA methylation results in altered gene expression in non-alcoholic steatohepatitis-related hepatocellular carcinomas. Journal of Cancer Research and Clinical Oncology, 146(10), 2461–2477. https://doi.org/10.1007/s00432-020-03298-4
Zhang, H., Guo, Y., Gu, H., Wei, X., Ma, W., Liu, D., et al. (2019). TRIM4 is associated with neural tube defects based on genome-wide DNA methylation analysis. Clinical Epigenetics, 11(1), 17. https://doi.org/10.1186/s13148-018-0603-z
Shim, H. S., Kenudson, M., Zheng, Z., Liebers, M., Cha, Y. J., Hoang Ho, Q., et al. (2015). Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. Journal of Thoracic Oncology, 10(8), 1156–1162. https://doi.org/10.1097/JTO.0000000000000579
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., et al. (2014). Anchored multiplex PCR for targeted next-generation sequencing. Nature Medicine, 20(12), 1479–1484. https://doi.org/10.1038/nm.3729
Shi, J., & He, L. (2023). Long-term use of anti-coronary heart disease medications may impact the serum zinc concentration. Biological Trace Element Research, 201(1), 1. https://doi.org/10.1007/s12011-022-03115-8
Vanden Bempt, I., Vander Borght, S., Sciot, R., Spans, L., Claerhout, S., Brems, H., et al. (2021). Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor. Genes, Chromosomes and Cancer, 60(4), 239–249. https://doi.org/10.1002/gcc.22923
Yeh, I., Botton, T., Talevich, E., Shain, A. H., Sparatta, A. J., de la Fouchardiere, A., et al. (2015). Activating MET kinase rearrangements in melanoma and Spitz tumours. Nature Communications, 6, 7174. https://doi.org/10.1038/ncomms8174
Bien, S. A., Su, Y. R., Conti, D. V., Harrison, T. A., Qu, C., Guo, X., et al. (2019). Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. Human Genetics, 138(4), 307–326. https://doi.org/10.1007/s00439-019-01989-8
Zhou, C., Zhang, Z., Zhu, X., Qian, G., Zhou, Y., Sun, Y., et al. (2020). N6-methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. EBioMedicine, 59, 102955. https://doi.org/10.1016/j.ebiom.2020.102955
Li, Y. J., Zhang, G. P., Zhao, F., Li, R. Q., Liu, S. J., Zhao, Z. R., et al. (2018). Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-kappaB signaling pathway. Experimental and Therapeutic Medicine, 15(3), 2365–2373. https://doi.org/10.3892/etm.2017.5679
Xi, X., Bao, Y., Zhou, Y., Chen, Y., Zhong, X., Liao, J., et al. (2021). Oncogenic gene TRIM10 confers resistance to cisplatin in osteosarcoma cells and activates the NF-kappaB signaling pathway. Cell Biology International, 45(1), 74–82. https://doi.org/10.1002/cbin.11468
Jiang, W., Cai, X., Xu, T., Liu, K., Yang, D., Fan, L., et al. (2020). Tripartite motif-containing 46 promotes viability and inhibits apoptosis of osteosarcoma cells by activating NF-B signaling through ubiquitination of PPAR. Oncology Research, 28(4), 409–421. https://doi.org/10.3727/096504020X15868639303417
Liang, J., Xing, D., Li, Z., Shen, J., Zhao, H., & Li, S. (2016). TRIM59 is upregulated and promotes cell proliferation and migration in human osteosarcoma. Molecular Medicine Reports, 13(6), 5200–5206. https://doi.org/10.3892/mmr.2016.5183
Chen, Y., Guo, Y., Yang, H., Shi, G., Xu, G., Shi, J., et al. (2015). TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates poor survival outcome. Oncotarget, 6(27), 23708–23719. https://doi.org/10.18632/oncotarget.4291
Liu, W., Zhao, Y., Wang, G., Feng, S., Ge, X., Ye, W., et al. (2022). TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling. Redox Biology, 53, 102344. https://doi.org/10.1016/j.redox.2022.102344
He, L. P., Song, Y. X., Zhu, T., Gu, W., & Liu, C. W. (2022). Progress in the relationship between vitamin D deficiency and the incidence of type 1 diabetes mellitus in children. Journal of Diabetes Research, 2022, 5953562. https://doi.org/10.1155/2022/5953562
Zhan, W., Han, T., Zhang, C., Xie, C., Gan, M., Deng, K., et al. (2015). TRIM59 promotes the proliferation and migration of non-small cell lung cancer cells by upregulating cell cycle related proteins. PLoS One, 10(11), e0142596. https://doi.org/10.1371/journal.pone.0142596
Dong, Z. R., Zhou, W., Sun, D., Yan, Y. C., Yang, C. C., Yang, Y. F., et al. (2020). Role of the E3 ubiquitin ligase TRIM4 in predicting the prognosis of hepatocellular carcinoma. Journal of Cancer, 11(14), 4007–4014. https://doi.org/10.7150/jca.37164
Hao, S., Zhu, J., Zhang, X., Qiu, J., Xuan, Q., & Ye, L. (2021). Comprehensive analysis of aerobic exercise-related genes identifies CDCA4 that promotes the progression of osteosarcoma. Frontiers in Genetics, 12, 637755. https://doi.org/10.3389/fgene.2021.637755
Li, C. P., Liu, X. H., Wang, X. J., & He, L. P. (2023). Trait creativity, personality, and physical activity: A structural equation model. Annals of Palliative Medicine, 12(1), 141–149. https://doi.org/10.21037/apm-22-1310
Author information
Authors and Affiliations
Contributions
Yan Li and Jie Gao carried out the experiments and drafted the manuscript; Dong Wang contributed to the immunohistochemistry experiments; Zijin Liu was involved in the statistical analysis; Huawu Zhang managed the experimental design, reviewed the manuscript, and provided funding support. All authors read and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Ethical Approval
Our study was approved by the Ethics Committee of Shandong Second Provincial General Hospital. All procedures involving people comply with the ethical standards of the institutional and/or national committee for research ethics and the 1964 Helsinki Declaration and its subsequent changes or comparable ethical standards.
Consent to Participate
The study was approved by the patient’s written consent and the institutional research ethics committee.
Consent for Publication
All other authors have read the manuscript and have agreed to submit it in its current form for consideration for publication in the Applied Biochemistry and Biotechnology.
Competing Interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Li, Y., Gao, J., Wang, D. et al. TRIM4 Expression Related to Malignant Progression and Cisplatin Resistance in Osteosarcoma. Appl Biochem Biotechnol 196, 233–244 (2024). https://doi.org/10.1007/s12010-023-04551-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12010-023-04551-5